Mutations of important oncogenic drivers, including ESR1, PIK3CA, CDK4/6, BRCA1/2, TP53, PTEN, and expressions of genes indicating immunotherapy or ADC targets contribute to selecting effective agents for metastatic breast cancer patients. The gene discussed is TP53; the disease is breast carcinoma.